ADVANCED SOLID TUMORS HARBORING RAS MUTATIONS OR AMPLIFICATIONS
Clinical trials for ADVANCED SOLID TUMORS HARBORING RAS MUTATIONS OR AMPLIFICATIONS explained in plain language.
Never miss a new study
Get alerted when new ADVANCED SOLID TUMORS HARBORING RAS MUTATIONS OR AMPLIFICATIONS trials appear
Sign up with your email to follow new studies for ADVANCED SOLID TUMORS HARBORING RAS MUTATIONS OR AMPLIFICATIONS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug targets Hard-to-Treat cancers with RAS mutations
Disease control Recruiting nowThis early-stage study tests a new drug called HRS-7172 in people with advanced solid tumors that have RAS gene mutations or amplifications. The main goals are to check the drug's safety, find the best dose, and see how the body processes it. About 120 adults aged 18-75 with good…
Matched conditions: ADVANCED SOLID TUMORS HARBORING RAS MUTATIONS OR AMPLIFICATIONS
Phase: PHASE1 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated May 18, 2026 12:01 UTC
-
New drug targets Hard-to-Treat cancers with RAS mutations
Disease control Recruiting nowThis early-stage study tests a new drug called HRS-2329 in people with advanced solid tumors that have RAS mutations or amplifications. The main goals are to check safety, find the best dose, and see how the drug moves through the body. About 120 adults aged 18-75 who have tried …
Matched conditions: ADVANCED SOLID TUMORS HARBORING RAS MUTATIONS OR AMPLIFICATIONS
Phase: PHASE1 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated May 18, 2026 11:59 UTC